Pharmaceutical industry
The announcement of a terrorist threat in the air travel sector has prompted a mixed reaction in airline stocks, with some experiencing losses and others gaining. According to Zacks.com's Analyst Blog, United Airlines (Nasdaq:UAUA) was flat, while Pinnacle Airlines (Nasdaq:PNCL) fell 2.7%. In contrast,
Pharmaceutical industry
Generex Biotechnology Corporation, the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced its presence at the American Association of Diabetes Educators (AADE) 33rd Annual Meeting & Exhibition. The conference, held August 10-12, 2006, at the Los Angeles Convention Center, aimed to provide the latest
Pharmaceutical industry
Men with advanced prostate cancer on androgen deprivation therapy (ADT) who received ACAPODENE had significantly lower total cholesterol, LDL, and triglyceride levels compared to placebo. The lipid interim analysis of the pivotal Phase III ADT clinical trial revealed a reduction in total cholesterol (-7.1%; p=0.001), LDL (-9.
Pharmaceutical industry
Ambrx, Inc., a biopharmaceutical company focused on optimizing existing protein drugs, has announced it has secured commitments for $52 million in Series C financing from a broad, international syndicate of new and existing investors. The financing will be used to further expand Ambrx's novel protein modification platform, support
Pharmaceutical industry
Decision Resources, Inc., a leading research and advisory firm, predicts that sales of Genentech/Roche/Chugai's Herceptin (trastuzumab) will nearly triple, reaching $3.3 billion in 2015. This forecast is based on positive data from several phase 3 clinical trials demonstrating improved disease-free survival of breast cancer patients.
Pharmaceutical industry
Sales of Genentech/Roche/Chugai's Herceptin (trastuzumab) are expected to reach $3.3 billion in 2015, nearly tripling its current sales. The growth is driven by the expansion of established agents, particularly Herceptin, into the adjuvant setting, which offers a larger patient pool and longer duration of therapy.
Pharmaceutical industry
Scientists at Generex Biotechnology's subsidiary, Antigen Express, have made significant progress in developing an immunotherapeutic peptide vaccine for breast cancer. The vaccine, currently in Phase I clinical trials, has shown promising results in preclinical studies conducted in collaboration with Dr. Constantin Baxevanis at the Saint Savas Cancer Hospital
Pharmaceutical industry
MorphoSys AG, a German-based biotechnology company, and OncoMed Pharmaceuticals, a U.S.-based biopharmaceutical company, have entered into a license agreement to utilize MorphoSys's HuCAL technology in the research and development of human therapeutic antibodies for cancer treatment. This collaboration aims to target cancer stem cells, a newly
Pharmaceutical industry
Novartis has taken a significant step in expanding its hepatitis C portfolio with an exclusive worldwide agreement to acquire the rights to Albuferon, an investigational drug developed by Human Genome Sciences (HGSI). Albuferon is poised to enter phase III clinical trials for the treatment of chronic hepatitis C infections and
Pharmaceutical industry
Safeguard Scientifics, Inc. has appointed Gary J. Kurtzman, MD, as its new vice president of life sciences. In this role, Kurtzman will focus on partnering with entrepreneurial companies in the life sciences sector, including medical devices, diagnostics, specialty pharmaceuticals, and technology-related services. He will also support Safeguard's existing
Pharmaceutical industry
ChemGenex Pharmaceuticals has initiated a new international trial of its leukemia drug, Ceflatonin, targeting patients with chronic myeloid leukemia (CML) who have developed resistance to the current treatment, Gleevec. This trial follows the recent grant of orphan drug status to Ceflatonin by the United States regulatory authority, indicating that the
Pharmaceutical industry
Carrington Laboratories, Inc.'s subsidiary DelSite Biotechnologies, Inc. has developed a technology that uses GelSite polymer to reduce the amount of antigen required for protective immunity by up to 16 times, enabling the expansion of one million standard doses to 16 million doses. This technology is crucial for addressing
